Carisma Therapeutics, Inc. – NASDAQ:CARM
Carisma Therapeutics stock price today
Carisma Therapeutics stock price monthly change
Carisma Therapeutics stock price quarterly change
Carisma Therapeutics stock price yearly change
Carisma Therapeutics key metrics
Market Cap | 17.06M |
Enterprise value | 10.82M |
P/E | -1.69 |
EV/Sales | 1.01 |
EV/EBITDA | -0.14 |
Price/Sales | 8.58 |
Price/Book | 1.96 |
PEG ratio | 0.01 |
EPS | -2 |
Revenue | 15.07M |
EBITDA | -81.49M |
Income | -81.21M |
Revenue Q/Q | 4.74% |
Revenue Y/Y | 22.99% |
Profit margin | -504.34% |
Oper. margin | -706.86% |
Gross margin | 100% |
EBIT margin | -706.86% |
EBITDA margin | -540.65% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCarisma Therapeutics stock price history
Carisma Therapeutics stock forecast
Carisma Therapeutics financial statements
| Jun 2023 | 3.56M | -19.87M | -558.31% |
|---|---|---|---|
| Sep 2023 | 3.82M | -21.40M | -559.26% |
| Dec 2023 | 4.28M | -20.95M | -488.65% |
| Mar 2024 | 3.39M | -18.97M | -558.67% |
| Sep 2025 | 4.28M | -18.78M | -437.91% |
|---|---|---|---|
| Oct 2025 | 3.59M | -15.69M | -436.1% |
| Dec 2025 | 12.43M | -24.17M | -194.34% |
| Dec 2025 | 3.59M | -17.05M | -474.03% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 133013000 | 66.30M | 49.85% |
|---|---|---|---|
| Sep 2023 | 106784000 | 60.48M | 56.64% |
| Dec 2023 | 89554000 | 63.02M | 70.37% |
| Mar 2024 | 73795000 | 62.9M | 85.24% |
| Jun 2023 | -18.54M | 35.75M | -3.63M |
|---|---|---|---|
| Sep 2023 | -20.99M | 29.81M | -2.03M |
| Dec 2023 | -16.24M | 10.43M | 247K |
| Mar 2024 | -22.42M | -17K | 1.35M |
Carisma Therapeutics alternative data
| Aug 2023 | 92 |
|---|---|
| Sep 2023 | 92 |
| Oct 2023 | 92 |
| Nov 2023 | 92 |
| Dec 2023 | 92 |
| Jan 2024 | 92 |
| Feb 2024 | 92 |
| Mar 2024 | 92 |
| Apr 2024 | 92 |
| May 2024 | 107 |
| Jun 2024 | 107 |
| Jul 2024 | 107 |
Carisma Therapeutics other data
-
What's the price of Carisma Therapeutics stock today?
One share of Carisma Therapeutics stock can currently be purchased for approximately $0.24.
-
When is Carisma Therapeutics's next earnings date?
Unfortunately, Carisma Therapeutics's (CARM) next earnings date is currently unknown.
-
Does Carisma Therapeutics pay dividends?
Yes, Carisma Therapeutics pays dividends and its trailing 12-month yield is 15.99% with 0% payout ratio. The last Carisma Therapeutics stock dividend of undefined was paid on 5 Sep 2025.
-
How much money does Carisma Therapeutics make?
Carisma Therapeutics has a market capitalization of 17.06M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 51.71% to 14.92M US dollars.
-
What is Carisma Therapeutics's stock symbol?
Carisma Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CARM".
-
What is Carisma Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Carisma Therapeutics?
Shares of Carisma Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Carisma Therapeutics have?
As Jul 2024, Carisma Therapeutics employs 107 workers, which is 16% more then previous quarter.
-
When Carisma Therapeutics went public?
Carisma Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 6 Feb 2014.
-
What is Carisma Therapeutics's official website?
The official website for Carisma Therapeutics is carismatx.com.
-
Where are Carisma Therapeutics's headquarters?
Carisma Therapeutics is headquartered at 3675 Market St., Philadelphia, PA.
-
How can i contact Carisma Therapeutics?
Carisma Therapeutics's mailing address is 3675 Market St., Philadelphia, PA and company can be reached via phone at +48 48990326.
Carisma Therapeutics company profile:
Carisma Therapeutics, Inc.
carismatx.comNASDAQ
107
Biotechnology
Healthcare
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Philadelphia, PA 19104
CIK: 0001485003
ISIN: US14216R1014
CUSIP: 14216R101
